PDF(Pubmed)
Abstract：
Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaque-type psoriasis in adults based on the evidence of two randomized and controlled phase-III clinical trials (reSURFACE 1 and reSURFACE 2). Here, we report our real-life experience treating 53 psoriatic patients (19 female and 34 male) who were administered tildrakizumab every 12 weeks and received follow-ups over 52 weeks. Descriptive and inferential statistical analyses were performed, in particular the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and, if applicable, the Nail Psoriasis Severity Index (NAPSI) and Palmoplantar Psoriasis Physician Global Assessment (PPPGA). These were assessed at baseline and after different timepoints (weeks) during the follow-up period. We described and evaluated demographical and epidemiological characteristics in our cohort group, focusing on comorbidities. In this group, 35.9% of patients were female and 64.1% were male, with 47.1% being smokers and with a mean age of 51.2 years. A total of 37.7% of these patients was affected by scalp psoriasis; regarding comorbidities, hypertension was the most frequent (32.5%), followed by psoriatic arthritis (PsA) (18.60%) and diabetes (13.9%). At week 52, 93%, 90.2% and 77% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. In addition, NAPSI, PPPGA and DLQI scores were significantly reduced by week 52. In our cohort of complex psoriasis patients, disease remission began at the end of the fourth week of treatment and remained constant from week 16 to week 52.
摘要：
Tildrakizumab是一种人源化IgG1κ单克隆抗体，可选择性靶向白细胞介素IL-23的p19亚基，从而抑制IL-23/IL-17轴，这主要与牛皮癣的免疫发病机制有关。根据两项随机对照III期临床试验（reSURFACE1和reSURFACE2）的证据，Tildrakizumab被批准用于治疗成人中重度斑块型银屑病。这里,我们报告了我们对53例银屑病患者(19例女性,34例男性)的真实治疗经验,这些患者每12周接受一次tildrakizumab,并接受了超过52周的随访.进行描述性和推断性统计分析，特别是牛皮癣面积和严重程度指数(PASI)，皮肤病生活质量指数（DLQI）和，如果适用，指甲银屑病严重程度指数（NAPSI）和掌plant银屑病医师全球评估（PPPGA）。这些在基线和随访期间的不同时间点(周)后进行评估。我们描述并评估了我们队列组的人口统计学和流行病学特征，专注于合并症。在这个群体中,35.9%的患者为女性，64.1%为男性，其中47.1%是吸烟者，平均年龄为51.2岁。总共37.7%的患者受到头皮银屑病的影响;关于合并症,高血压是最常见的（32.5%），其次是银屑病关节炎（PsA）（18.60%）和糖尿病（13.9%）。在第52周，93%，90.2%和77%的患者实现了PASI降低≥75%(PASI75)，分别为PASI90和PASI100。此外,NAPSI,PPPGA和DLQI评分在第52周时显著降低。在我们的复杂银屑病患者队列中，疾病缓解在第4周治疗结束时开始,从第16周到第52周保持不变.
